These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31009237)

  • 21. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
    Myers SH; Brunton VG; Unciti-Broceta A
    J Med Chem; 2016 Apr; 59(8):3593-608. PubMed ID: 26555154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
    Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
    Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3D-QSAR and Molecular Docking Studies on Design Anti-Prostate Cancer Curcumin Analogues.
    Meng X; Cui L; Song F; Luan M; Ji J; Si H; Duan Y; Zhai H
    Curr Comput Aided Drug Des; 2020; 16(3):245-256. PubMed ID: 30370853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational analyses of curcuminoid analogs against kinase domain of HER2.
    Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
    BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The three dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists.
    Xu G; Chu Y; Jiang N; Yang J; Li F
    Int J Mol Sci; 2012; 13(5):6138-6155. PubMed ID: 22754355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
    Balupuri A; Balasubramanian PK; Cho SJ
    Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells.
    Kim KC; Baek SH; Lee C
    Int J Oncol; 2015 Dec; 47(6):2296-303. PubMed ID: 26498137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient Arylation of 2,7-Naphthyridin-1(2
    Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W
    ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 34. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
    Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
    Gajiwala KS; Grodsky N; Bolaños B; Feng J; Ferre R; Timofeevski S; Xu M; Murray BW; Johnson TW; Stewart A
    J Biol Chem; 2017 Sep; 292(38):15705-15716. PubMed ID: 28724631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
    Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
    J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors.
    Tan L; Zhang Z; Gao D; Chan S; Luo J; Tu ZC; Zhang ZM; Ding K; Ren X; Lu X
    Eur J Med Chem; 2019 Mar; 166():318-327. PubMed ID: 30731400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment.
    Li MC; Lai YL; Kuo PH; Reddy JS; Chen CM; Manimala J; Wang PC; Wu MS; Chang CY; Yang CM; Lin CY; Huang YC; Chiu CH; Chang L; Lin WH; Yeh TK; Yen WC; Hsieh HP
    J Med Chem; 2024 Jul; 67(13):10906-10927. PubMed ID: 38913493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.